首頁 > 市場調查報告書 > 製藥

再生醫學

市場調查報告書

商品編碼

1449602

全球誘導性多功能幹細胞市場：按細胞來源、按應用、按最終用戶、按地區

Global Induced Pluripotent Stem Cells Market, By Cell Source, By Application, By End User, By Geography

出版日期: 2024年02月09日 | 出版商:

Coherent Market Insights | 英文 164 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，誘導性多功能幹細胞的全球市值為15.954億美元，預計2024年至2031年年複合成長率為11.1%，到2031年達到37.07億美元。

報告範圍		報告詳情
基準年	2023年	2023/2024年市場規模	15.954 億美元
實際資料	2019-2023	預測期	2024-2031
預測期間2023/2024 至2030/2031年年複合成長率：	11.10%	2030/2031年預測值	37.07億美元

圖 1.誘導性多功能幹細胞的全球市場佔有率（%），依地區分類，2024年

誘導性多功能幹細胞（iPSC）是一種可以直接從成人細胞產生的多功能細胞。誘導性多功能幹細胞的發現徹底改變了再生醫學領域，因為它提供了倫理上優於胚胎幹細胞的替代品。誘導性多功能幹細胞（iPSC）是一種經過基因重編程形成類似胚胎幹細胞的多功能狀態的成體細胞。 iPSC 用於再生醫學研究，以研究疾病機制、藥物發現和毒性篩檢。 iPSC 的再生特性為開發以細胞為基礎的治療方法提供了機會。透過引進或過度表達關鍵轉錄因子，這些細胞將由多功能的成體細胞重新編程，使它們在分化潛力和多能性標記物的表達方面回歸到與胚胎幹細胞相似的狀態。該技術對於開發用於藥物發現、毒性篩檢和再生治療的患者和疾病特異性幹細胞模型具有廣闊的前景。

市場動態：

全球誘導性多功能幹細胞市場的推動因素包括慢性病的增加、器官移植的增加以及生物製藥公司為開發利用幹細胞的新型治療方法而增加的研發投資。然而，iPS 細胞研究和臨床應用的高成本以及細胞重編程和幹細胞分化的技術挑戰限制市場的成長。同時，幹細胞技術不斷進步，包括標準培養方法的開拓、無異源重編程方法的開發以及大規模幹細胞生產的進步，預計將為市場參與者提供利潤豐厚的成長機會。

本研究的主要特點

本報告詳細分析了全球誘導性多功能幹細胞市場，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率。
揭示了不同細分市場的潛在收益成長機會，並解釋了該市場有吸引力的投資提案矩陣。
提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點，實績和策略等參數對全球誘導性多功能幹細胞市場的主要企業進行了分析。
本報告重點介紹了 Takara Bio、Thermo Fisher Scientific、 FUJIFILM Holdings Holdings、 Astellas Pharma、Fate Therapeutics、Ncardia、ViaCyte、Cellular Dynamics International、Lonza、Blueprint Medicines 和其他主要企業。
本報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球誘導性多功能幹細胞市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師。
相關人員可以透過用於分析全球誘導性多功能幹細胞市場的各種策略矩陣來促進他們的決策。

北美洲
美國
加拿大
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
歐洲
德國
英國
西班牙
法國
義大利
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
澳洲
韓國
ASEAN
其他亞太地區
中東
海灣合作理事會國家
以色列
其他中東地區
非洲
南非
北非
中部非洲

第9章競爭格局

公司簡介
- Takara Bio Inc.
- Thermo Fisher Scientific
- Fujifilm Holdings Corporation
- Astellas Pharma
- Fate Therapeutics
- Ncardia
- ViaCyte
- Cellular Dynamics International
- Lonza
- Blueprint Medicines
- Other Prominent Players

第10章

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI6630

The global induced pluripotent stem cells market was valued at US$ 1,595.4 Mn in 2023 and is expected to reach US$ 3,707 Mn by 2031, growing at a compound annual growth rate (CAGR) of 11.1% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 1,595.4 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	11.10%	2030/2031 Value Projection:	US$ 3,707 Mn

Figure 1. Global Induced Pluripotent Stem Cells Market Share (%), By Region, 2024

Global Induced Pluripotent Stem Cells Market - IMG1

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The discovery of induced pluripotent stem cells revolutionized the field of regenerative medicine as it provided an ethically superior alternative to embryonic stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like pluripotent state. iPSCs are used in regenerative medicine research to study mechanisms of disease and for drug discovery and toxicity screening. Regenerative properties of iPSCs provide opportunities for developing cell-based therapies. These cells are reprogrammed from their original differentiated adult cells through the introduction or overexpression of key transcription factors that enable them to regress to a state that resembles embryonic stem cells in terms of differentiation potential and expression of pluripotency markers. This technology holds tremendous promise for developing patient and disease specific stem cell models for drug discovery, toxicity screening, and regenerative therapies.

Market Dynamics:

Global induced pluripotent stem cells market is driven by rising prevalence of chronic diseases, increasing adoption of organ transplantation and growing research and development (R&D) investments by biopharmaceutical companies for developing novel stem cell-based therapies. However, high costs that are associated with iPSC research and clinical applications, technical challenges in cell reprogramming and stem cell differentiation are restraining wider market growth. Meanwhile, ongoing advancements in stem cell technologies including establishment of standard culture practices, development of xeno-free reprogramming methods and progress in large-scale stem cell production are expected to offer lucrative growth opportunities for market players.

Key features of the study:

This report provides an in-depth analysis of the global induced pluripotent stem cells market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global induced pluripotent stem cells market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
The key companies covered as a part of this study include Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines, and Other Prominent Players.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global induced pluripotent stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global induced pluripotent stem cells market.

Detailed Segmentation:

By Cell Source:
- Skin derived iPSCs
- Blood derived iPSCs
- Urine Derived iPSCs
- Hepatocytes derived iPSCs
- Lung fibroblast derived iPSCs
- Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
By Application:
- Culture & Maintenance
- Differentiation
- Genetic Manipulation & Engineering
- Characterization & Validation
- Banking & Storage
- Others (Reprogramming kits, Analysis software etc.)
By End User:
- Hospitals
- Diagnostics Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Others (Academic & Research Institutes etc.)
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Top Companies in the Global Induced Pluripotent Stem Cells Market
- Takara Bio Inc.
- Thermo Fisher Scientific
- Fujifilm Holdings Corporation
- Astellas Pharma
- Fate Therapeutics
- Ncardia
- ViaCyte
- Cellular Dynamics International
- Lonza
- Blueprint Medicines
- Other Prominent Players

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Induced Pluripotent Stem Cells Market Snippet, By Cell Source
- Global Induced Pluripotent Stem Cells Market Snippet, By Application
- Global Induced Pluripotent Stem Cells Market Snippet, By End User
- Global Induced Pluripotent Stem Cells Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Induced Pluripotent Stem Cells Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Induced Pluripotent Stem Cells Market, By Cell Source, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Skin derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Blood derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Urine Derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Hepatocytes derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Lung fibroblast derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Induced Pluripotent Stem Cells Market, By Application, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Culture & Maintenance
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Differentiation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Genetic Manipulation & Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Characterization & Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Banking & Storage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Others (Reprogramming kits, Analysis software etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Induced Pluripotent Stem Cells Market, By End User, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Diagnostics Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Pharmaceutical & Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Contract Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Others (Academic & Research Institutes etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Induced Pluripotent Stem Cells Market, By Region, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020 - 2031
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
South Africa
North Africa
Central Africa

9. Competitive Landscape

Company Profile
- Takara Bio Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Thermo Fisher Scientific
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Fujifilm Holdings Corporation
- Astellas Pharma
- Fate Therapeutics
- Ncardia
- ViaCyte
- Cellular Dynamics International
- Lonza
- Blueprint Medicines
- Other Prominent Players
Analyst Views